RGC

BEARISH

$28.67 Live

Regencell Bioscience Holdings Limited · NASDAQ

$0.7 52W Range $83.6

RGC Regencell Bioscience Holdings Limited - Fundamental Analysis

BEARISH

Console Chart News

RGC Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic

Current Price Live

$28.67

52W High

$83.6

52W Low

$0.7

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$14.18B

P/E

N/A

ROE

-54.8%

Profit margin

N/A

Debt/Equity

0.11

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

95%

Regencell Bioscience (RGC) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. The company is currently trading at an astronomical Price-to-Book ratio of 2867.00, indicating a massive disconnect between market price and tangible asset value. With 0% profit margins and a negative ROE of -54.81%, the company lacks the operational efficiency to justify its $14.18B market capitalization. Despite historical price surges, the current technical trend is 0/100 (Bearish), suggesting a speculative bubble that has lost momentum.

Key Strengths

Very low Debt/Equity ratio (0.11)

Strong short-term liquidity with a Current Ratio of 7.39

High Quick Ratio (7.38) indicating minimal reliance on inventory for liquidity

Massive historical price appreciation over 1, 3, and 5-year horizons

Low leverage compared to healthcare sector average (3.24)

Key Risks

Extreme overvaluation as evidenced by a Price/Book ratio of 2867.00

Complete lack of profitability with 0% gross, operating, and profit margins

Significant negative returns on equity (-54.81%) and assets (-33.20%)

Bearish technical trend (0/100) following a period of extreme volatility

Total absence of analyst coverage and earnings estimates

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Bubble

Key drivers: Extreme P/B ratio, Weak Piotroski F-Score, Zero profitability, Bearish technicals

Confidence

90%

Value

0/100

Graham Number is unavailable; valuation is entirely decoupled from fundamentals.

Positives

No standout positives identified.

Watchpoints

P/B ratio of 2867.00 is unsustainable
No P/E or PEG available due to lack of earnings

Future

20/100

Future value is purely speculative without growth metrics.

Positives

Operates in high-growth Healthcare sector

Watchpoints

No reported revenue growth data
No earnings progression

Past

60/100

Historical performance reflects a momentum-driven rally rather than value creation.

Positives

Exceptional 1Y (+3641%) and 5Y (+10275%) price returns

Watchpoints

Price gains are not supported by fundamental growth

Health

30/100

Strong liquidity is offset by poor operational health and negative ROE.

Positives

Low debt levels
High current ratio

Watchpoints

Piotroski F-Score of 3/9 indicates poor financial health

Dividend

0/100

Company does not return capital to shareholders.

Positives

No standout positives identified.

Watchpoints

No dividend yield
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$28.67

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RGC and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
RGC Regencell Bioscience Holdings Limited Primary	+10275.8%	+3861.7%	+3641.3%	+64.7%	+8.7%	-0.5%
PODD Insulet Corporation Peer	-28.4%	-37.3%	-19.6%	-36.3%	-12.6%	+1.0%
MEDP Medpace Holdings, Inc. Peer	+181.9%	+160.9%	+64.2%	-5.0%	+11.3%	+1.1%
ASND Ascendis Pharma A/S Peer	+53.7%	+106.6%	+48.4%	+15.5%	+2.0%	-6.1%
BBIO BridgeBio Pharma, Inc. Peer	+18.4%	+720.5%	+110.0%	+68.2%	+1.8%	+2.1%

RGC

Regencell Bioscience Holdings Limited

Primary

+10275.8%

+3861.7%

+3641.3%

+64.7%

+8.7%

-0.5%

POD

Insulet Corporation

Peer

-28.4%

-37.3%

-19.6%

-36.3%

-12.6%

+1.0%

MED

Medpace Holdings, Inc.

Peer

+181.9%

+160.9%

+64.2%

-5.0%

+11.3%

+1.1%

ASN

Ascendis Pharma A/S

Peer

+53.7%

+106.6%

+48.4%

+15.5%

+2.0%

-6.1%

BBI

BridgeBio Pharma, Inc.

Peer

+18.4%

+720.5%

+110.0%

+68.2%

+1.8%

+2.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

2867.0

N/A

-3838.44

$14.18B

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin N/A

Gross Margin N/A

ROE -54.81%

ROA -33.2%

Growth

Revenue and earnings growth rates

Revenue Growth N/A

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.11

Low debt

Current Ratio

7.39

Strong

Quick Ratio

7.38

Excellent

Cash/Share

$0.01

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Total Assets

$0.0B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

0.11x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-06-02

$N/A

2025-11-18

$N/A

2025-07-16

$N/A

Healthcare Sector Comparison

Comparing RGC against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)

Return on Equity (ROE)

-54.81%

This Stock

-97.91%

Sector Avg

-44.0% (Below Avg)

Debt to Equity

0.11

This Stock

3.0

Sector Avg

-96.3% (Less Debt)

Current Ratio

7.39

This Stock

4.65

Sector Avg

+58.8% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
RGC Regencell Bioscience...	BEARISH	$14.18B	-	-54.8%	-%	$28.67
PODD Insulet Corporation	NEUTRAL	$14.18B	57.73	18.1%	9.1%	$201.47	Compare
MEDP Medpace Holdings, Inc.	NEUTRAL	$14.31B	32.76	70.2%	17.8%	$501.23	Compare
ASND Ascendis Pharma A/S	BULLISH	$13.87B	-	-%	-31.7%	$225.98	Compare
BBIO BridgeBio Pharma, Inc.	BEARISH	$14.92B	-	-%	-225.3%	$77.87	Compare

RGC Regencell...

BEARISH

Mkt Cap

$14.2B

P/E

ROE

-54.8%

Price

$28.67

PODD Insulet Corporation

Compare with RGC

MEDP Medpace Holdings, Inc.

Compare with RGC

ASND Ascendis Pharma A/S

Compare with RGC

BBIO BridgeBio Pharma, Inc.

Compare with RGC

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

ANNUAL REPORT

2025-10-31

RGC filed its Form 20-F annual report on October 31, 2025. Due to the limited information provided, specific financial highlights and risk factors are not available for summary.

20-F

ANNUAL REPORT

2024-10-25

RGC filed its annual report on Form 20-F on October 25, 2024. Specific financial highlights and risk factors were not provided in the available metadata.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning RGC from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

RGC

RGC Regencell Bioscience Holdings Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Past News Coverage

Wait — Don't Miss Out!